RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311

Benzinga · 4d ago
RBC Capital analyst Gregory Renza maintains BeiGene (NASDAQ:ONC) with a Outperform and lowers the price target from $312 to $311.